Table II.
Hospitalizations or ED visits: Values are odds ratio (95% CI) (p value) for severe exacerbations in vitamin D insufficient group (≤30 ng/ml) vs. vitamin D sufficient group (>30ng/ml)
| Unadjusted odds ratio | Adjusted for age, sex, BMI, income, treatment group1 |
Additionally adjusted for season of vitamin D draw |
Additionally adjusted for baseline asthma severity |
Additionally adjusted for race |
|
|---|---|---|---|---|---|
| Retrospective analysis2 | |||||
| ED or hospitalization in year prior to study3 |
1.7 (1.3 – 2.2) (.0002) | 1.9 (1.4 – 2.5) (<.0001) |
2.0 (1.5 – 2.7) (<.0001) |
1.9 (1.4 – 2.6) (<.0001) |
1.7 (1.2 – 2.7) (.001) |
| Prospective analysis | |||||
| ED/Hospitalization over 4 years of study |
1.3 (1.0 – 1.7) (.05) | 1.5 (1.1 – 1.9) (.01) | 1.5 (1.2 – 2.1) (.004) | 1.5 (1.1 – 2.0) (.006) | 1.4 (1.0 – 1.9) (.03) |
| Vitamin D insufficiency at baseline (placebo or nedocromil) |
1.2 (0.9 – 1.6) (.36) | 1.3 (1.0 – 1.9) (.08) | 1.4 (1.0 – 2.0) (.03) | 1.4 (1.0 – 2.0) (.06) | 1.3 (.9 – 1.8) (.15) |
| Vitamin D insufficiency at baseline(budesonide) |
1.7 (1.0 – 2.8) (.06) | 1.8 (1.0 – 3.2) (.05) | 1.8 (1.0 – 3.3) (.06) | 1.8 (1.0 – 3.4) (.05) | 1.7 (.9 – 3.2) (.11) |
1
Models for hospitalization prior to randomization and stratified models are not adjusted for treatment group.
2
The terms retrospective and prospective refer to the timing of the outcomes relative to the timing of phlebotomy from which vitamin D levels were measured.